AbCellera Biologics Valuation: Undervalued by 77.4% Despite 16.8% Weekly Share Price Drop

Friday, Jan 30, 2026 1:42 am ET1min read
ABCL--

AbCellera Biologics shares have dropped 16.8% in the past week, with a 12.5% year-to-date return. The stock last closed at $3.86, and our valuation checks score it 2/6. Using a discounted cash flow analysis, the estimated intrinsic value per share is $17.05, implying the stock is 77.4% undervalued under these assumptions.

AbCellera Biologics Valuation: Undervalued by 77.4% Despite 16.8% Weekly Share Price Drop

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet